Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis C

  Free Subscription


Articles published in J Hepatol

Retrieve available abstracts of 163 articles:
HTML format
Text format



Single Articles


    May 2017
  1. COLPITTS CC, Baumert TF
    SCARB1 variants and HCV infection: Host susceptibility is lost in translation.
    J Hepatol. 2017 May 3. pii: S0168-8278(17)30255.
    PubMed     Text format    


    April 2017
  2. BANKWITZ D, Doepke M, Hueging K, Weller R, et al
    Maturation of secreted HCV particles by incorporation of secreted apoE protects from antibodies by enhancing infectivity.
    J Hepatol. 2017 Apr 21. pii: S0168-8278(17)30251.
    PubMed     Text format     Abstract available


  3. KAWAGISHI N, Suda G, Onozawa M, Kimura M, et al
    Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection.
    J Hepatol. 2017 Apr 21. pii: S0168-8278(17)30249.
    PubMed     Text format     Abstract available


  4. BRUNO S, Maisonneuve P
    Response to the letter regarding the manuscript "Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population".
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30216.
    PubMed     Text format    


  5. HALLAGER S, Ladelund S, Weis N
    Methodological considerations when calculating person time at risk for patients with chronic hepatitis C undergoing antiviral treatment.
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30218.
    PubMed     Text format    


  6. KWO PY, Poordad F, Asatryan A, Wang S, et al
    Glecaprevir and Pibrentasvir Yield High response Rates in Patients with HCV Genotype 1-6 without Cirrhosis.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30211.
    PubMed     Text format     Abstract available


  7. THONS C, Senff T, Hydes TJ, Manser AR, et al
    HLA-Bw4 80(T) and multiple HLA-Bw4 copies combined with KIR3DL1 associate with spontaneous clearance of HCV infection in people who inject drugs.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30213.
    PubMed     Text format     Abstract available


  8. VAN SANTEN DK, Van Der Helm JJ, Del Amo J, Meyer L, et al
    Lack of decline in Hepatitis C Virus incidence among HIV-positive men who have sex with men during 1990-2014.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30209.
    PubMed     Text format     Abstract available


  9. ZIMMERMANN R, Kollan C, Ingiliz P, Mauss S, et al
    Reply to "Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030".
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30204.
    PubMed     Text format    


  10. DORE GJ, Grebely J
    Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30206.
    PubMed     Text format    


  11. TUMINO N, Casetti R, Fabbri G, Cimini E, et al
    In HIV/HCV co-infected patients T regulatory and myeloid derived suppressor cells persist after successful treatment with directly acting antivirals.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30207.
    PubMed     Text format    


  12. HASSON H, Merli M, Messina E, Bhoori S, et al
    Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30203.
    PubMed     Text format     Abstract available


  13. LANGHANS B
    Reply to "In HIV/HCV co-infected patients T regulatory and myeloid derived suppressor cells persist after successful treatment with directly acting antivirals".
    J Hepatol. 2017 Apr 9. pii: S0168-8278(17)30205.
    PubMed     Text format    


  14. SCHWARZINGER M, Baillot S, Yazdanpanah PY, Rehm PJ, et al
    Contribution of Alcohol Use Disorders on the Burden of Chronic Hepatitis C in France, 2008-2013: A Nationwide Retrospective Cohort Study.
    J Hepatol. 2017 Apr 7. pii: S0168-8278(17)30202.
    PubMed     Text format     Abstract available


    March 2017
  15. WESTHAUS S, Deest M, Nguyen AT, Stanke F, et al
    Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load.
    J Hepatol. 2017 Mar 28. pii: S0168-8278(17)30184.
    PubMed     Text format     Abstract available


  16. WELZEL T, Bhardwaj N, Hedskog C, Chodavarapu K, et al
    Global Epidemiology of HCV Subtypes and Resistance-associated Substitutions Evaluated by Sequencing-Based Subtype Analyses.
    J Hepatol. 2017 Mar 23. pii: S0168-8278(17)30148.
    PubMed     Text format     Abstract available


  17. MARTIN NK, Vickerman P, Hickman M
    How to eliminate HCV infection by antiviral treatment.
    J Hepatol. 2017 Mar 17. pii: S0168-8278(17)30142.
    PubMed     Text format    


  18. BESTE LA, Green PK, Berry K, Kogut MJ, et al
    Effectiveness of hepatitis c antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.
    J Hepatol. 2017 Mar 3. pii: S0168-8278(17)30126.
    PubMed     Text format     Abstract available


    February 2017
  19. PIROTH L, Wittkop L, Lacombe K, Rosenthal E, et al
    Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-coinfected patients - French ANRS CO13 HEPAVIH cohort.
    J Hepatol. 2017 Feb 21. pii: S0168-8278(17)30107.
    PubMed     Text format     Abstract available


  20. RAMOS-CASALS M, Zignego AL, Ferri C, Brito-Zeron P, et al
    Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection.
    J Hepatol. 2017 Feb 17. pii: S0168-8278(17)30105.
    PubMed     Text format     Abstract available


  21. OLIVIERO B, Mantovani S, Varchetta S, Mele D, et al
    Hepatitis C virus-Induced NK Cell Activation Causes Metzincin-Mediated CD16 Cleavage and Impaired Antibody-Dependent Cytotoxicity.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30069.
    PubMed     Text format     Abstract available


  22. CABIBBO G, Petta S, Barbara M, Attardo S, et al
    Hepatic Decompensation is the Major Driver of Death In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30070.
    PubMed     Text format     Abstract available


  23. ZENG QL, Xu GH, Zhang JY, Li W, et al
    Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: a real-life observational study.
    J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30060.
    PubMed     Text format     Abstract available


  24. ZIMMERMANN R, Kollan C, Ingiliz P, Mauss S, et al
    Real-world treatment for chronic hepatitis C infection in Germany. Analyses from drug prescription data, 2010 - 2015.
    J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30059.
    PubMed     Text format     Abstract available


  25. CALLEJA JL, Crespo J, Rincon D, Ruiz-Antoran B, et al
    Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real world cohort.
    J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30063.
    PubMed     Text format     Abstract available


  26. GREBELY J, Swan T, Hickman M, Bruneau J, et al
    Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C.
    J Hepatol. 2017 Feb 3. pii: S0168-8278(17)30054.
    PubMed     Text format    


  27. PAWLOTSKY JM
    Consistent advice for people who inject drugs in the 2016 EASL Recommendations on treatment of hepatitis C.
    J Hepatol. 2017 Feb 3. pii: S0168-8278(17)30055.
    PubMed     Text format    


  28. PRENNER S, VanWagner LB, Flamm SL, Salem R, et al
    Hepatocellular Carcinoma Decreases the Chance of Successful Hepatitis C Virus Therapy with Direct-Acting Antivirals.
    J Hepatol. 2017 Feb 1. pii: S0168-8278(17)30053.
    PubMed     Text format     Abstract available


    January 2017
  29. FARQUHAR MJ, Humphreys IS, Rudge SA, Wilson GK, et al
    Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.
    J Hepatol. 2017 Jan 23. pii: S0168-8278(17)30013.
    PubMed     Text format     Abstract available


  30. ZEUZEM S, Mizokami M, Pianko S, Mangia A, et al
    NS5A Resistance-Associated Substitutions in Patients with Genotype 1 Hepatitis C Virus: Prevalence and Effect on Treatment Outcome.
    J Hepatol. 2017 Jan 17. pii: S0168-8278(17)30011.
    PubMed     Text format     Abstract available


  31. KLAG T, Dietz J, Werner CR, Schwarz JM, et al
    Hepatitis C "true" late relapse beyond 48 weeks of sustained virologic response after direct acting antiviral therapy.
    J Hepatol. 2017 Jan 9. pii: S0168-8278(17)30006.
    PubMed     Text format    


    December 2016
  32. LANGHANS B, Dieter Nischalke H, Kramer B, Hausen A, et al
    Increased peripheral cd4+ regulatory t cells persist after successful direct-acting antiviral treatment of chronic hepatitis C.
    J Hepatol. 2016 Dec 28. pii: S0168-8278(16)30752.
    PubMed     Text format     Abstract available


  33. FERNANDEZ I, Munoz-Gomez R, Pascasio JM, Baliellas C, et al
    Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis c.
    J Hepatol. 2016 Dec 27. pii: S0168-8278(16)30753.
    PubMed     Text format     Abstract available


  34. VUKOTIC R, Conti F, Andreone P
    Hepatitis C virus eradication in elderly: The challenge worth a long-life elixir?
    J Hepatol. 2016 Dec 21. pii: S0168-8278(16)30745.
    PubMed     Text format    


  35. MANGIA A, Susser S, Piazzolla V, Agostinacchio E, et al
    Sofosbuvir and Ribavirin for genotype 2 HCV infected patients with cirrhosis: a real life experience.
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30707.
    PubMed     Text format     Abstract available


  36. WYLES D, Dvory-Sobol H, Svarovskaia Doehle ES, Martin R, et al
    Post-Treatment Resistance Analysis of Hepatitis C Virus from Phase 2 and 3 Clinical Trials of Ledipasvir/ Sofosbuvir.
    J Hepatol. 2016 Dec 3. pii: S0168-8278(16)30699.
    PubMed     Text format     Abstract available


    November 2016
  37. TOYODA H, Kumada T, Tada T, Shimada N, et al
    Efficacy and Tolerability of an IFN-free Regimen with DCV/ASV for Elderly Patients Infected with HCV Genotype 1B.
    J Hepatol. 2016 Nov 24. pii: S0168-8278(16)30686.
    PubMed     Text format     Abstract available


  38. HELLARD M, Pedrana A, Scott N
    Targeted direct-acting antiviral treatment for chronic hepatitis C: a financial reality or an obstacle to elimination?
    J Hepatol. 2016 Nov 21. pii: S0168-8278(16)30680.
    PubMed     Text format    


  39. TSAI PC, Huang CF, Yu ML
    Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: issue of tie interval between HCC treatment and antiviral therapy.
    J Hepatol. 2016 Nov 10. pii: S0168-8278(16)30646.
    PubMed     Text format    


  40. JANJUA NZ, Chong M, Kuo M, Woods R, et al
    Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    J Hepatol. 2016 Nov 3. pii: S0168-8278(16)30637.
    PubMed     Text format     Abstract available


  41. FALADE-NWULIA O, Sulkowski M
    The HCV care continuum does not end with cure: A call to arms for the prevention of reinfection.
    J Hepatol. 2016 Nov 2. pii: S0168-8278(16)30636.
    PubMed     Text format    


    October 2016
  42. VAN DER MEER AJ, Feld JJ, Hofer H, Almasio PL, et al
    Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
    J Hepatol. 2016 Oct 22. pii: S0168-8278(16)30582.
    PubMed     Text format     Abstract available


  43. DEUFFIC-BURBAN S, Boursier J, Leroy V, Yazdanpanah Y, et al
    Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis?
    J Hepatol. 2016 Oct 12. pii: S0168-8278(16)30568.
    PubMed     Text format     Abstract available


  44. ROSS DB, Belperio PS, Chartier M, Backus LI, et al
    Hepatitis C Testing in U.S. Veterans Born 1945-1965: An Update.
    J Hepatol. 2016 Oct 5. pii: S0168-8278(16)30557.
    PubMed     Text format    


  45. JUSTICE AC, Esserman D, Sarkar S, Levin FL, et al
    Reply to: "Disparities in Hepatitis C Testing in U.S. Veterans Born 1945-1965".
    J Hepatol. 2016 Oct 4. pii: S0168-8278(16)30558.
    PubMed     Text format    


  46. VAN DER MEER AJ, Berenguer M
    Reversion of disease manifestations after HCV eradication.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  47. CACOUB P, Desbois AC, Isnard-Bagnis C, Rocatello D, et al
    Hepatitis C virus infection and chronic kidney disease: Time for reappraisal.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  48. MAASOUMY B, Vermehren J
    Diagnostics in hepatitis C: The end of response-guided therapy?
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  49. EASTERBROOK PJ
    Who to test and how to test for chronic hepatitis C infection - 2016 WHO testing guidance for low- and middle-income countries.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  50. MIDGARD H, Weir A, Palmateer N, Lo Re V 3rd, et al
    HCV epidemiology in high-risk groups and the risk of reinfection.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  51. HEIM MH, Bochud PY, George J
    Host - hepatitis C viral interactions: The role of genetics.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  52. BUKH J
    The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  53. MORADPOUR D, Grakoui A, Manns MP
    Future landscape of hepatitis C research - Basic, translational and clinical perspectives.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  54. YOUNOSSI ZM, Birerdinc A, Henry L
    Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  55. FORNS X, Berg T
    Hepatitis C virus - A teacher of clinical research, cell biology and immunology.
    J Hepatol. 2016;65.
    PubMed     Text format    


    September 2016
  56. INGILIZ P, Martin TC, Rodger A, Stellbrink HJ, et al
    HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe.
    J Hepatol. 2016 Sep 17. pii: S0168-8278(16)30505.
    PubMed     Text format     Abstract available



  57. EASL Recommendations on Treatment of Hepatitis C 2016.
    J Hepatol. 2016 Sep 12. pii: S0168-8278(16)30489.
    PubMed     Text format    


  58. POL S, Bourliere M, Lucier S, Hezode C, et al
    Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
    J Hepatol. 2016 Sep 10. pii: S0168-8278(16)30486.
    PubMed     Text format     Abstract available


  59. WANG H, Tai AW
    Continuous de novo generation of spatially segregated hepatitis C virus replication organelles revealed by pulse-chase imaging.
    J Hepatol. 2016 Sep 3. pii: S0168-8278(16)30483.
    PubMed     Text format     Abstract available


    August 2016
  60. ZAVAGLIA C, Okolicsanji S, Cesarini L, Mazzarelli C, et al
    Is the risk of neoplastic recurrence increased after prescribing Direct Acting Antivirals for HCV patients whose HCC was previously cured?
    J Hepatol. 2016 Aug 31. pii: S0168-8278(16)30481.
    PubMed     Text format    


  61. WAZIRY R, Grebely J, Amin J, Alavi M, et al
    Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014).
    J Hepatol. 2016 Aug 25. pii: S0168-8278(16)30442.
    PubMed     Text format     Abstract available


  62. INNES H, McDonald S, Hayes P, Dillon JF, et al
    Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population.
    J Hepatol. 2016 Aug 18. pii: S0168-8278(16)30428.
    PubMed     Text format     Abstract available


  63. HEDEGAARD DL, Tully DC, Rowe IA, Reynolds GM, et al
    High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end stage liver disease.
    J Hepatol. 2016 Aug 13. pii: S0168-8278(16)30424.
    PubMed     Text format     Abstract available


  64. MINAMI T, Tateishi R, Nakagomi R, Fujiwara N, et al
    The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma.
    J Hepatol. 2016 Aug 11. pii: S0168-8278(16)30419.
    PubMed     Text format    


  65. ROBAEYS G, Rob B, Azar DG, Razavi H, et al
    Global genotype distribution of hepatitis C viral infection among people who inject drugs.
    J Hepatol. 2016 Aug 9. pii: S0168-8278(16)30418.
    PubMed     Text format     Abstract available


  66. EBERHARD JM, Kummer S, Hartjen P, Hufner A, et al
    Reduced CD161+MAIT cell frequencies in HCV and HIV/HCV co-infection. Is the liver the heart of the matter?
    J Hepatol. 2016 Aug 1. pii: S0168-8278(16)30401.
    PubMed     Text format     Abstract available


    July 2016
  67. CARDOSO H, Vale AM, Rodrigues S, Goncalves R, et al
    High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis.
    J Hepatol. 2016 Jul 28. pii: S0168-8278(16)30397.
    PubMed     Text format    


  68. ZENG QL, Li ZQ, Liang HX, Xu GH, et al
    Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming?
    J Hepatol. 2016 Jul 28. pii: S0168-8278(16)30399.
    PubMed     Text format    


  69. VIONNET J, Saouli AC, Pascual M, Stucker F, et al
    Therapeutic Drug Monitoring for Sofosbuvir and Daclatasvir in Transplant Recipients with Chronic Hepatitis C and Advanced Renal Disease.
    J Hepatol. 2016 Jul 25. pii: S0168-8278(16)30347.
    PubMed     Text format    


  70. DEGASPERI E, De Nicola S, Rumi M, D'Ambrosio R, et al
    HCV-RNA Kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin.
    J Hepatol. 2016 Jul 23. pii: S0168-8278(16)30344.
    PubMed     Text format    


  71. DESNOYER A, Le MP, Yazdanpanah Y, Peytavin G, et al
    Reply to: "Therapeutic Drug Monitoring for Sofosbuvir and Daclatasvir in Transplant Recipients with Chronic Hepatitis C and Advanced Renal Disease".
    J Hepatol. 2016 Jul 23. pii: S0168-8278(16)30345.
    PubMed     Text format    


  72. MAASOUMY B, Vermehren J, Wedemeyer H, Sarrazin C, et al
    Clinical value of on-treatment HCV-RNA levels during treatment with sofosbuvir and ribavirin in genotype 3 patients.
    J Hepatol. 2016 Jul 23. pii: S0168-8278(16)30343.
    PubMed     Text format    


  73. ALAVI M, Law MG, Grebely J, Amin J, et al
    Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: a population-based study, 1995-2012.
    J Hepatol. 2016 Jul 8. pii: S0168-8278(16)30321.
    PubMed     Text format     Abstract available


  74. YANG JD, Aqel BA, Pungpapong S, Gores GJ, et al
    Direct Acting Antiviral Therapy and Tumor Recurrence after Liver Transplant for Hepatitis C-Associated Hepatocellular Carcinoma.
    J Hepatol. 2016 Jul 5. pii: S0168-8278(16)30318.
    PubMed     Text format    


  75. CHEUNG MC, Walker AJ, Hudson BE, Verma S, et al
    Outcomes after successful direct acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.
    J Hepatol. 2016 Jul 4. pii: S0168-8278(16)30314.
    PubMed     Text format     Abstract available


    June 2016
  76. CONTI F, Buonfiglioli F, Scuteri A, Crespi C, et al
    Early Occurrence and Recurrence of Hepatocellular Carcinoma in HCV-related Cirrhosis Treated with Direct Acting Antivirals.
    J Hepatol. 2016 Jun 24. pii: S0168-8278(16)30303.
    PubMed     Text format     Abstract available


  77. COILLY A, Fougerou-Leurent C, de Ledinghen V, Houssel-Debry P, et al
    Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence after liver transplantation - The CO23 ANRS CUPILT study.
    J Hepatol. 2016 Jun 1. pii: S0168-8278(16)30253.
    PubMed     Text format     Abstract available


    May 2016
  78. MANDORFER M, Kozbial K, Schwabl P, Freissmuth C, et al
    Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension.
    J Hepatol. 2016 May 27. pii: S0168-8278(16)30238.
    PubMed     Text format     Abstract available


  79. TSENG A, Wong DK
    Hepatotoxicity and Potential Drug Interaction with Ledipasvir/Sofosbuvir In HIV/HCV Infected Patients.
    J Hepatol. 2016 May 19. pii: S0168-8278(16)30201.
    PubMed     Text format     Abstract available


  80. VANDENBULCKE H, Moreno C, Colle I, Knebel JF, et al
    Alcohol intake increases the risk of hepatocellular carcinoma in patients with hepatitis C virus-related compensated cirrhosis: a prospective study.
    J Hepatol. 2016 May 12. pii: S0168-8278(16)30184.
    PubMed     Text format     Abstract available


  81. BULTEEL N, Sarathy PP, Forrest E, Stanley AJ, et al
    Factors Associated with Spontaneous Clearance of Chronic Hepatitis c Virus Infection: a Retrospective Case Control Study.
    J Hepatol. 2016 May 4. pii: S0168-8278(16)30182.
    PubMed     Text format     Abstract available


  82. PADEGIMAS A, Forde KA, Goldberg LR, Birati EY, et al
    Myo-pericarditis secondary to ledipasvir-sofosbuvir therapy.
    J Hepatol. 2016;64:1196-8.
    PubMed     Text format    


    April 2016
  83. FOSTER G
    Reply to: "High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme".
    J Hepatol. 2016 Apr 27. pii: S0168-8278(16)30142.
    PubMed     Text format    


  84. GRAY E, O'Leary A, Stewart S, Bergin C, et al
    High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme.
    J Hepatol. 2016 Apr 27. pii: S0168-8278(16)30143.
    PubMed     Text format    


  85. SARKAR S, Esserman DA, Skanderson M, Levin FL, et al
    Disparities in Hepatitis C Testing in U.S. Veterans Born 1945-1965.
    J Hepatol. 2016 Apr 26. pii: S0168-8278(16)30144.
    PubMed     Text format     Abstract available


  86. MAASOUMY B, Vermehren J, Welker MW, Bremer B, et al
    Clinical value of on-treatment HCV RNA levels during different approved sofosbuvir-based antiviral regimens.
    J Hepatol. 2016 Apr 13. pii: S0168-8278(16)30108.
    PubMed     Text format     Abstract available


  87. REIG M, Marino Z, Perello C, Inarrairaegui M, et al
    Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution.
    J Hepatol. 2016 Apr 12. pii: S0168-8278(16)30113.
    PubMed     Text format     Abstract available


  88. BHAMIDIMARRI KR, Martin P
    Finally safe and effective treatment options for hepatitis C in hemodialysis patients.
    J Hepatol. 2016 Apr 9. pii: S0168-8278(16)30105.
    PubMed     Text format    


  89. LUNEMANN S, Martrus G, Holzemer A, Chapel A, et al
    Sequence variations in HCV core-derived epitopes alter binding of KIR2DL3 to HLA-C03:04 and modulate NK cell function.
    J Hepatol. 2016 Apr 4. pii: S0168-8278(16)30097.
    PubMed     Text format     Abstract available


  90. MEHTA SH, Thomas DL
    Doing the math on hepatitis C virus treatment.
    J Hepatol. 2016 Apr 2. pii: S0168-8278(16)30096.
    PubMed     Text format    


    March 2016
  91. BRUNO S, Di Marco V, Iavarone M, Roffi L, et al
    Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.
    J Hepatol. 2016 Mar 23. pii: S0168-8278(16)00075.
    PubMed     Text format     Abstract available


  92. YOUNOSSI ZM, Stepanova M, Feld J, Zeuzem S, et al
    Sofosbuvir/Velpatasvir Improves Patient-Reported Outcomes in HCV Patients: Results from ASTRAL-1 Placebo-Controlled Trial.
    J Hepatol. 2016 Mar 5. pii: S0168-8278(16)30008.
    PubMed     Text format     Abstract available


  93. DESNOYER A, Pospai D, Le MP, Gervais A, et al
    Sofosbuvir-containing regimen for HCV infection in hemodialysis patients: 400 mg daily or only on the day of hemodialysis.
    J Hepatol. 2016 Mar 4. pii: S0168-8278(16)30010.
    PubMed     Text format     Abstract available


    February 2016
  94. JACKA B, Applegate T, Poon AF, Raghwani J, et al
    Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada.
    J Hepatol. 2016 Feb 25. pii: S0168-8278(16)00165.
    PubMed     Text format     Abstract available


  95. ZAHND C, Salazar-Vizcaya L, Dufour JF, Mullhaupt B, et al
    Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfected men who have sex with men.
    J Hepatol. 2016 Feb 24. pii: S0168-8278(16)00164.
    PubMed     Text format     Abstract available


  96. MOSTAFA A, Shimakawa Y, Medhat A, Mikhail NN, et al
    Excess mortality rate associated with hepatitis C virus infection: a community-based cohort study in rural Egypt.
    J Hepatol. 2016 Feb 24. pii: S0168-8278(16)00167.
    PubMed     Text format     Abstract available


  97. DAHARI H, Canini L, Graw F, Uprichard SL, et al
    HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.
    J Hepatol. 2016 Feb 20. pii: S0168-8278(16)00153.
    PubMed     Text format     Abstract available


  98. STEVEN FOX D, McCombs JS
    Optimizing HCV Treatment - Moving Beyond the Cost Conundrum.
    J Hepatol. 2016 Feb 11. pii: S0168-8278(16)00089.
    PubMed     Text format    


  99. MARTIN NK, Vickerman P, Dore GJ, Grebely J, et al
    How should HCV treatment be prioritized in the direct-acting antiviral era? An economic evaluation including population prevention benefits.
    J Hepatol. 2016 Feb 8. pii: S0168-8278(16)00086.
    PubMed     Text format     Abstract available


    January 2016
  100. FOSTER GR, Irving WL, Cheung MC, Walker AJ, et al
    Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.
    J Hepatol. 2016 Jan 29. pii: S0168-8278(16)00065.
    PubMed     Text format     Abstract available


  101. UDOMPAP P, Mannalithara A, Heo N, Kim D, et al
    Increasing Prevalence of Cirrhosis among US Adults Aware or Unaware of their Chronic Hepatitis C Virus Infection.
    J Hepatol. 2016 Jan 22. pii: S0168-8278(16)00014.
    PubMed     Text format     Abstract available


  102. YANG YH, Chen WC, Tsai YH, Chen PC, et al
    Reply to "Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection".
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00011.
    PubMed     Text format    


  103. HOOFNAGLE JH
    Hepatic Decompensation during Direct-Acting Antiviral Therapy of Chronic Hepatitis C.
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00010.
    PubMed     Text format    


  104. YU ML
    Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection.
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00012.
    PubMed     Text format    


  105. MIDGARD H, Bjoro B, Maeland A, Konopski Z, et al
    Hepatitis C Reinfection Following Sustained Virological Response - Seven-Year Follow-Up Of Patients Infected Through Injecting Drug Use.
    J Hepatol. 2016 Jan 9. pii: S0168-8278(16)00003.
    PubMed     Text format     Abstract available


  106. BAUMERT TF, Schuster C, Cosset FL, Dubuisson J, et al
    Addressing the Next Challenges: a Summary of the 22nd International Symposium on Hepatitis C Virus and Related Viruses.
    J Hepatol. 2016 Jan 9. pii: S0168-8278(16)00004.
    PubMed     Text format     Abstract available


  107. YOUNOSSI ZM, Stepanova M, Estep M, Negro F, et al
    Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin.
    J Hepatol. 2016;64:29-36.
    PubMed     Text format     Abstract available


    December 2015
  108. HULLEGIE SJ, Claassen MA, van den Berk GE, van der Meer JT, et al
    A 12-Week Treatment with Boceprevir, Peginterferon and Ribavirin for Acute Hepatitis C in HIV infected patients.
    J Hepatol. 2015 Dec 12. pii: S0168-8278(15)00805.
    PubMed     Text format     Abstract available


  109. MARCHAN-LOPEZ A, Dominguez-Dominguez L, Kessler-Saiz P, Jarrin-Estupinan ME, et al
    Liver Failure in Human Immunodeficiency Virus - Hepatitis C Virus Coinfection Treated with Sofosbuvir, Ledipasvir and Antiretroviral Therapy.
    J Hepatol. 2015 Dec 9. pii: S0168-8278(15)00799.
    PubMed     Text format    


  110. DYSON JK, McPherson S
    Reply to "Liver Failure in Human Immunodeficiency Virus - Hepatitis C Virus Coinfection Treated with Sofosbuvir, Ledipasvir and Antiretroviral Therapy".
    J Hepatol. 2015 Dec 9. pii: S0168-8278(15)00800.
    PubMed     Text format    


    November 2015
  111. WELKER MW, Luhne S, Lange CM, Vermehren J, et al
    Lactic acidosis in patients with hepatitis C virus related cirrhosis and combined ribavirin/sofosbuvir treatment.
    J Hepatol. 2015 Nov 30. pii: S0168-8278(15)00792.
    PubMed     Text format     Abstract available


  112. SHIELS MS, Robbins HA, Engels EA
    Letter to the editor on "Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010".
    J Hepatol. 2015 Nov 7. pii: S0168-8278(15)00726.
    PubMed     Text format    


  113. ALLISON RD, Holmberg SD
    Response to comment on "Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010".
    J Hepatol. 2015 Nov 7. pii: S0168-8278(15)00729.
    PubMed     Text format    


    October 2015
  114. FELD JJ, Moreno C, Trinh R, Tam E, et al
    Sustained Virologic Response of 100% in HCV Genotype 1b Patients with Cirrhosis Receiving Ombitasvir/Paritaprevir/r and Dasabuvir for 12 Weeks.
    J Hepatol. 2015 Oct 14. pii: S0168-8278(15)00676.
    PubMed     Text format     Abstract available


  115. ZEUZEM S, Hezode C, Bronowicki JP, Loustaud-Ratti V, et al
    Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.
    J Hepatol. 2015 Oct 7. pii: S0168-8278(15)00672.
    PubMed     Text format     Abstract available


    September 2015
  116. SARRAZIN C
    The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.
    J Hepatol. 2015 Sep 24. pii: S0168-8278(15)00629.
    PubMed     Text format     Abstract available


  117. HEZODE C, Bronowicki JP
    Ideal oral combinations to eradicate HCV. The role of ribavirin.
    J Hepatol. 2015 Sep 24. pii: S0168-8278(15)00627.
    PubMed     Text format     Abstract available


  118. YAN M, Ha J, Aguilar M, Bhuket T, et al
    Birth Cohort-Specific Disparities in Hepatocellular Carcinoma Stage at Diagnosis, Treatment, and Long-term Survival.
    J Hepatol. 2015 Sep 16. pii: S0168-8278(15)00623.
    PubMed     Text format     Abstract available


  119. COILLY A, Samuel D
    Pros and Cons: Usage of organs from donors infected with hepatitis C virus - revision in the direct acting antiviral era.
    J Hepatol. 2015 Sep 12. pii: S0168-8278(15)00617.
    PubMed     Text format     Abstract available


  120. GERBER L, Younossi Z
    Fatigue in Patients with Chronic Hepatitis C.
    J Hepatol. 2015 Sep 12. pii: S0168-8278(15)00616.
    PubMed     Text format    


  121. PAWLOTSKY JM, Aghemo A, Back D, Dusheiko G, et al
    Should HCV-infected patients with debilitating fatigue be prioritized for treatment with interferon-free regimens?
    J Hepatol. 2015 Sep 12. pii: S0168-8278(15)00619.
    PubMed     Text format    


  122. KHATRI A, Menon R
    Reply to comments on: Pharmacokinetics and Safety of Coadministered Paritaprevir plus Ritonavir (Paritaprevir/r), Ombitasvir, and Dasabuvir in Hepatic Impairment.
    J Hepatol. 2015 Sep 5. pii: S0168-8278(15)00612.
    PubMed     Text format    


  123. CHTIOUI H, Buclin T
    Pharmacokinetics and Safety of Coadministered Paritaprevir plus Ritonavir (Paritaprevir/r), Ombitasvir, and Dasabuvir in Hepatic Impairment.
    J Hepatol. 2015 Sep 4. pii: S0168-8278(15)00610.
    PubMed     Text format    


    August 2015
  124. DORE GJ, Conway B, Luo Y, Janczewska E, et al
    Randomized trials of ombitasvir/paritaprevir/r+dasabuvir+/-ribavirin vs telaprevir+pegIFN/ribavirin in adults with genotype 1 HCV.
    J Hepatol. 2015 Aug 27. pii: S0168-8278(15)00557.
    PubMed     Text format     Abstract available


  125. WOLTER F, Glassner A, Kramer B, Kokordelis P, et al
    Hypoxia impairs anti-viral activity of natural killer (NK) cells but has little effect on anti-fibrotic NK cell functions in hepatitis C virus infection.
    J Hepatol. 2015 Aug 19. pii: S0168-8278(15)00550.
    PubMed     Text format     Abstract available


  126. GRANCINI V, Trombetta M, Lunati ME, Zimbalatti D, et al
    Contribution of beta-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: role of severity of liver disease.
    J Hepatol. 2015 Aug 19. pii: S0168-8278(15)00553.
    PubMed     Text format     Abstract available


  127. BRUNO R, Aghemo A
    Hepatitis C Virus Post-exposure prophylaxis: a reasonable option in the era of pangenotypic directly acting antivirals?
    J Hepatol. 2015 Aug 18. pii: S0168-8278(15)00549.
    PubMed     Text format    


  128. HJERRILD S, Dalgard O, Christensen PB, Leutscher P, et al
    Debilitating fatigue as a treatment indication in chronic hepatitis C.
    J Hepatol. 2015 Aug 8. pii: S0168-8278(15)00540.
    PubMed     Text format    


  129. HUNG GY, Horng JL, Yen HJ, Lee CY, et al
    Changing Incidence Patterns of Hepatocellular Carcinoma Among Age Groups in Taiwan.
    J Hepatol. 2015 Aug 6. pii: S0168-8278(15)00534.
    PubMed     Text format     Abstract available


  130. GREBELY J, Haire B, Taylor LE, Macneill P, et al
    Excluding people who use drugs or alcohol from access to hepatitis C treatments - Is this fair, given the available data?
    J Hepatol. 2015 Aug 4. pii: S0168-8278(15)00406.
    PubMed     Text format    


    July 2015
  131. EL-SHAMY A, Eng FJ, Doyle EH, Klepper AL, et al
    A Cell Culture System for Distinguishing Hepatitis C Viruses with and without Liver Cancer-related Mutations in the Viral Core Gene.
    J Hepatol. 2015 Jul 25. pii: S0168-8278(15)00515.
    PubMed     Text format     Abstract available


  132. YANG YH, Chen WC, Tsan YT, Chen MJ, et al
    Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection.
    J Hepatol. 2015 Jul 18. pii: S0168-8278(15)00469.
    PubMed     Text format     Abstract available


  133. O'BRIEN TR, Pfeiffer RM, Paquin A, Lang Kuhs KA, et al
    Comparison of Functional Variants in IFNL4 and IFNL3 for Association with Hepatitis C Virus Clearance.
    J Hepatol. 2015 Jul 14. pii: S0168-8278(15)00465.
    PubMed     Text format     Abstract available


  134. ARENDS JE, Lieveld F, Boeijen LL, de Kanter CT, et al
    Natural history and treatment of Hepatitis C/HIV coinfection: is it time to change paradigms?
    J Hepatol. 2015 Jul 14. pii: S0168-8278(15)00462.
    PubMed     Text format     Abstract available


    June 2015
  135. SONG ZZ
    Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.
    J Hepatol. 2015 Jun 30. pii: S0168-8278(15)00416.
    PubMed     Text format    


  136. FERENCI P, Kozbial K, Mandorfer M, Hofer H, et al
    HCV targeting of patients with cirrhosis.
    J Hepatol. 2015 Jun 19. pii: S0168-8278(15)00393.
    PubMed     Text format     Abstract available


  137. BHAMIDIMARRI K, Czul F, Peyton A, Levy C, et al
    Safety, efficacy and tolerability of Simeprevir plus half-dose Sofosbuvir in treatment of Hepatitis C in patients with end stage renal disease.
    J Hepatol. 2015 Jun 18. pii: S0168-8278(15)00394.
    PubMed     Text format    


  138. KHATRI A, Menon R, Marbury TC, Lawitz E, et al
    Pharmacokinetics and Safety of Coadministered Paritaprevir plus Ritonavir (Paritaprevir/r), Ombitasvir, and Dasabuvir in Hepatic Impairment.
    J Hepatol. 2015 Jun 10. pii: S0168-8278(15)00387.
    PubMed     Text format     Abstract available


  139. KOUTSOUDAKIS G, Romero-Brey I, Berger C, Perez-Vilaro G, et al
    Soraphen A: a broad-spectrum antiviral natural product with potent anti-hepatitis C virus activity.
    J Hepatol. 2015 Jun 9. pii: S0168-8278(15)00391.
    PubMed     Text format     Abstract available


    May 2015
  140. RICARDO-LAX I, Ramanan V, Michailidis E, Shamia T, et al
    Hepatitis B virus induces RNR-R2 expression via DNA damage response activation.
    J Hepatol. 2015 May 27. pii: S0168-8278(15)00344.
    PubMed     Text format     Abstract available


  141. SELVAPATT N, Ward T, Bailey H, Bennett H, et al
    Is antenatal screening for hepatitis C virus cost effective? A decade's experience at a London centre.
    J Hepatol. 2015 May 26. pii: S0168-8278(15)00342.
    PubMed     Text format     Abstract available


  142. MEHTA G, Dusheiko G
    Hepatitis C treatment and quality of life - you can't always get what you want, but you might get what you need.
    J Hepatol. 2015 May 13. pii: S0168-8278(15)00326.
    PubMed     Text format    


    April 2015
  143. KITSON MT, Sarrazin C, Toniutto P, Roberts SK, et al
    Reply to 'Evidence supporting a beneficial role of vitamin D in chronic hepatitis C'.
    J Hepatol. 2015 Apr 18. pii: S0168-8278(15)00295.
    PubMed     Text format    


  144. PAWLIK TM, Soubrane O
    Metabolic syndrome-associated hepatocellular carcinoma: questions still unanswered.
    J Hepatol. 2015 Apr 7. pii: S0168-8278(15)00245.
    PubMed     Text format    


    March 2015
  145. DELTENRE P
    Studies on the epidemiology of hepatitis B and C virus infections are still needed.
    J Hepatol. 2015 Mar 5. pii: S0168-8278(15)00162.
    PubMed     Text format    


    February 2015
  146. SIMON TG, King LY, Chung RT
    Coagulation and fibrosis: a potential non-negligible target of statins in chronic hepatitis.
    J Hepatol. 2015 Feb 26. pii: S0168-8278(15)00138.
    PubMed     Text format    


  147. BITTO N, Salerno F, Tripodi A, Mura V, et al
    Coagulation and fibrosis: a potential non-negligible target of statins in chronic hepatitis.
    J Hepatol. 2015 Feb 25. pii: S0168-8278(15)00137.
    PubMed     Text format    


    January 2015
  148. NEGRO F
    Are statins a remedy for all seasons?
    J Hepatol. 2015;62:8-10.
    PubMed     Text format    


    November 2014
  149. GAMBATO M, Lens S, Navasa M, Forns X, et al
    Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation.
    J Hepatol. 2014;61.
    PubMed     Text format     Abstract available


    July 2014
  150. HUANG Y, de Boer WB, Adams LA, MacQuillan G, et al
    Image analysis of liver biopsy samples measures fibrosis and predicts clinical outcome.
    J Hepatol. 2014;61:22-7.
    PubMed     Text format     Abstract available


  151. CHIAVAROLI L, Ha V, Kendall CW, Sievenpiper JL, et al
    Is industrial fructose just a marker of an unhealthy dietary pattern?
    J Hepatol. 2014;61:172-3.
    PubMed     Text format    


  152. PETTA S, Marchesini G, Craxi A
    Reply to: "is industrial fructose just a marker of an unhealthy dietary pattern?".
    J Hepatol. 2014;61:173-5.
    PubMed     Text format    


    June 2014
  153. NISCHALKE HD, Lutz P, Kramer B, Sohne J, et al
    A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease.
    J Hepatol. 2014 Jun 16. pii: S0168-8278(14)00401.
    PubMed     Text format     Abstract available


    May 2014
  154. BOETTLER T, Moradpour D, Thimme R, Zoulim F, et al
    Bridging Basic Science and Clinical Research - The EASL Monothematic Conference on Translational Research in Viral Hepatitis.
    J Hepatol. 2014 May 15. pii: S0168-8278(14)00357.
    PubMed     Text format     Abstract available


  155. ROMERO-GOMEZ M, Berenguer M, Molina E, Calleja JL, et al
    Reply to: "Renal impairment and anemia during triple therapy".
    J Hepatol. 2014;60:1100-1.
    PubMed     Text format    


  156. VESPASIANI-GENTILUCCI U, Gallo P, Picardi A
    Renal impairment and anemia during triple therapy.
    J Hepatol. 2014;60:1099-100.
    PubMed     Text format    


    April 2014
  157. EDER E, Scherzer TM, Hofer H, Ferenci P, et al
    Reply to: "DHEA and progesterone have a protective effect on ribavirin-induced hemolysis".
    J Hepatol. 2014;60:898-9.
    PubMed     Text format    


  158. BROCHOT E, Bodeau S, Nguyen-Khac E, Duverlie G, et al
    DHEA and progesterone have a protective effect on ribavirin-induced hemolysis.
    J Hepatol. 2014;60:897-8.
    PubMed     Text format    


  159. HEZODE C, Fontaine H, Barthe Y, Carrat F, et al
    Reply to: "From the CUPIC study: great times are not coming(?)".
    J Hepatol. 2014;60:900-1.
    PubMed     Text format    


  160. SCHMIDT-MARTIN D, Houlihan D, McCormick A
    From the CUPIC study: great times are not coming(?).
    J Hepatol. 2014;60:899-900.
    PubMed     Text format    


  161. SAMAIN A, Duval-Modeste AB, Joly P, Leblanc C, et al
    First case of drug rash eosinophilia and systemic symptoms due to boceprevir.
    J Hepatol. 2014;60:891-3.
    PubMed     Text format     Abstract available


    March 2014
  162. KULIK L, Vouche M, Koppe S, Lewandowski RJ, et al
    Prospective Randomized Pilot Study of Y90 +/- Sorafenib as Bridge to Transplantation in Hepatocellular Carcinoma.
    J Hepatol. 2014 Mar 26. pii: S0168-8278(14)00204.
    PubMed     Text format     Abstract available


    January 2014
  163. VAN DER MEER AJ, Feld JJ, Zeuzem S, Janssen HL, et al
    Reply to: 'Evidence recommending antiviral therapy in hepatitis C'
    J Hepatol. 2014 Jan 17. pii: S0168-8278(14)00052.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: